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The immune system has evolved effective mech-
anisms using a limited number of Ig genes to de-
fend against a plethora of pathogens. To produce a 
diverse repertoire of antibodies, B cells undergo a 
series of genetic alterations to create a much 
greater variety of antibodies than specified by the 
number  of  Ig  genes.  Somatic  hypermutation 
(SHM) is one of the diversification processes in 
activated B cells. SHM requires the activity of a 
mutation factor, activation-induced cytosine de-
aminase (AID; Muramatsu et al. 2000), and tran-
scription of the target gene (Storb et al., 2001; 
Barreto et al., 2005). In many studies, the mu-
tation frequencies of Ig genes were found to 
correlate positively with the level of transcrip-
tion (Bachl et al., 2001). The frequency and the 
range of mutations depended on the distance 
of the targeted sequences from the promoter 
(Lebecque and Gearhart, 1990; Motoyama et al.,   
1994; Rada et al., 1994; Rogerson, 1994; Wu 
and Claflin, 1998; Rada and Milstein, 2001), 
and initiation of transcription inside an Ig gene 
induced SHM at the distal constant region that 
is normally unmutated (Peters and Storb, 1996). 
SHM targets Ig genes at high rates and several 
other non-Ig genes, such as BCL6, at interme-
diate rates (Pasqualucci et al., 1998; Shen et al., 
1998;  Müschen et al., 2000; Gordon et al., 2003), 
and  may  target  all  other  transcribed  genes  at 
very low frequencies (Liu et al., 2008).
The specific association of AID with the mu-
table target genes is likely to be regulated by cis-
elements within or near the target genes. The Ig 
enhancers are required for SHM in endogenous 
Ig genes. Deletion of either intronic or 3 en-
hancer regions in Ig transgenes eliminated or 
drastically decreased SHM (Betz et al., 1994). The 
Ig enhancers comprise multiple cis-elements, 
all of which also occur in other enhancers in one 
combination or another. A previous study in our 
laboratory  showed  that  the  presence  of  two 
CAGGTG motifs in addition to the four CAG-
GTG and eight CAGCTG motifs already pres-
ent in an Ig transgene greatly enhanced the 
frequency of SHM without increasing transcrip-
tion (Michael et al., 2003). The CAGGTG motif 
is present in Ig heavy and light chain enhancers 
that are shown to be required for Ig expression 
and SHM, as well as in all of the frequent non- 
Ig targets of SHM, such as BCL6 (Pasqualucci   
et al., 1998; Shen et al., 1998). Moreover, T cell 
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The process of somatic hypermutation (SHM) of immunoglobulin (Ig) genes requires 
activation-induced cytidine deaminase (AID). Although mistargeting of AID is detrimental 
to genome integrity, the mechanism and the cis-elements responsible for targeting of AID 
are largely unknown. We show that three CAGGTG cis-elements in the context of Ig 
enhancers are sufficient to target SHM to a nearby transcribed gene. The CAGGTG motif 
binds E47 in nuclear extracts of the mutating cells. Replacing CAGGTG with AAGGTG in 
the construct without any other E47 binding site eliminates SHM. The CA versus AA 
effect requires AID. CAGGTG does not enhance transcription, chromatin acetylation, or 
overall target gene activity. The other cis-elements of Ig enhancers alone cannot attract 
the SHM machinery. Collectively with other recent findings, we postulate that AID targets 
all genes expressed in mutating B cells that are associated with CAGGTG motifs in the 
appropriate context. Ig genes are the most highly mutated genes, presumably because of 
multiple CAGGTG motifs within the Ig genes, high transcription activity, and the presence 
of other cooperating elements in Ig enhancers.
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CAGCTG to CCGCTG. This change does not alter the amino 
acid coding, and thus, neomycin resistance was preserved. 
This makes the C-GFP construct transgene have only three 
CAGGTG motifs in the entire construct and no other CAG-
GTG, CACCTG, CAGCTG, or CACGTG motifs, whereas 
the A-GFP transgene is completely devoid of these motifs.
To monitor SHM targeting, we inserted a premature 
stop codon in the GFP gene and a 300-bp spacer from the 
mutable region of the human BCL6 gene to position this 
stop codon at the peak of the mutable region observed in Ig 
genes. The spacer from BCL6 does not contain any CAG-
GTG sites. We chose it because it was known not to inter-
fere  with  continuous  SHM  in  its  vicinity.  This  seemed 
important because we had shown that a transcriptional pro-
moter placed in front of the C region can initiate a new 
wave of mutations (Peters and Storb,1996), and we sus-
pected that anything inhibiting transcription elongation may 
affect the progress of SHM further 3. For cells transfected 
with these transgenes to express functional GFP, they must 
mutate the stop codon. Because this stop codon is also part 
of  an  AID  hotspot  (GYW),  it  should  have  a  reasonable 
chance of being mutated by AID.
Both the C-GFP and A-GFP constructs were transfected 
into an actively mutating chicken B cell line, DT40 CL18 
(Sale et al., 2001), and stably transfected clones were selected. 
To verify SHM in this study, GFP fluorescence must be 
linked directly to a mutation of the premature stop codon by 
DNA sequencing. In cells where multiple copies of the trans-
gene are integrated, mutation of a premature stop codon in 
one of the transgene copies may escape detection by PCR 
cloning and sequencing analyses. Therefore, for accurate as-
sessment of SHM activity, independent C-GFP and A-GFP 
clones with only a single copy of the respective transgene 
were selected by Southern blot analyses (unpublished data).
Because SHM depends on transcription levels as well as 
transcription initiation (Peters and Storb, 1996), we further 
selected clones with equivalent levels of transgene transcrip-
tion. To assess the levels of stable transcripts as a measure of 
lymphomas from mice with overexpressed transgenic AID 
indicated that all of the mutated genes found in these tumors 
shared the CAGGTG motif in the enhancer and/or promoter 
(Kotani et al., 2005).
These findings showed that CAGGTG was an enhancer of 
SHM but did not test whether CAGGTG is sufficient/re-
quired to attract AID to a nearby gene. To determine whether 
the CAGGTG motif is sufficient/required for SHM targeting, 
we generated mutable GFP transgenes that contained either 
three CAGGTG motifs or no CAGGTG motif in the entire 
construct. Our findings show that SHM occurs with otherwise 
identical transgenes only when they contain CAGGTG motifs.
RESULTS
Transgenic DT40 cell lines
To address whether the presence of the CAGGTG motif is 
required for targeting of SHM, we generated a mutable en-
hanced GFP (eGFP) transgene containing three CAGGTG 
motifs (C-GFP) and a control transgene containing AAGGTG   
(A-GFP) but completely lacking the CAGGTG motif. The 
transgenes have GFP and neomycin resistance genes driven 
by individual CMV promoters (Fig. 1).
Because SHM in an Ig transgene context requires both an 
intronic enhancer/matrix attachment region and a 3 enhancer 
(Betz et al., 1994), we used enhancers from a mouse Ig gene. 
These enhancers contain one CAGGTG motif in the intronic 
enhancer and two CACCTG motifs in the 3 enhancer, which 
are the reverse complements of CAGGTG. In the A-GFP 
transgene, these CAGGTG motifs were changed to AAGGTG   
or AACCTG, motifs that showed no enhancement of SHM 
frequency when present in an Ig transgene (Michael et al., 
2003). Because one of the binding factors known to bind the 
CAGGTG motif is an E47 homodimer, a predominant form 
of E protein in the B cell lineage, we also considered much 
weaker  binding  motifs  of  the  E47  homodimer,  such  as 
CAGCTG and CACGTG (Hsu et al., 1994). To eliminate the 
possibility of E47 homodimer binding to CAGCTG, which 
is present in the neomycin resistance gene, we changed this 
Figure 1.  C-GFP and A-GFP transgenes. The C-GFP transgene contains three CAGGTG (CACCTG) motifs and the A-GFP transgene is completely de-
void of the CAGGTG motif. The individual components are CMV promoter, eGFP, splice and poly A signals from SV40, intronic enhancer and matrix attach-
ment regions from the mouse Ig  gene, neomycin resistance gene driven by the CMV promoter, and 3 enhancer from the mouse Ig  gene. The Blp I site 
was used to linearize the plasmid. The primer pair used for sequencing is indicated with black arrows; the primer pair used for the ChIP assay is shown 
with blue arrows with an asterisk.JEM VOL. 207, February 15, 2010 
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eliminates the possibility that the difference in the occurrence 
of SHM was caused by varied transcription levels of the target 
genes. Furthermore, the AID mRNA levels were also equiv-
alent among all 10 clones (P > 0.1; Fig. 2), indicating that the 
enhanced mutation frequencies of the C-GFP clones are in-
dependent of variability in AID expression.
The GFP premature stop codon is mutated
To analyze GFP sequences for mutations, sorted GFP+ cells 
from C-GFP and A-GFP subclones were cultured for 1 wk 
before DNA cloning and sequencing (Fig. 4 A). Although 
there were a few A-GFP clones with GFP+ cells, the A2-4 
subclone (Fig. 3) was the only A-GFP subclone from which 
we were able to sort enough viable GFP+ cells to culture and 
expand for genomic DNA isolation. Sequencing analyses of 
the GFP region of C-GFP clones showed that 86% of the se-
quences contained a mutation at the premature stop codon 
(121 out of 141 sequences; Fig. 5). These were mostly G-to-C 
transversions at the third nucleotide of the stop codon. The 
SHM frequency of the GFP-expressing C-GFP clones was 
1.38 × 103 mutations/bp. This is comparable to the SHM 
frequency of 3.05 × 103 in DT40 cells selected for loss of 
membrane Ig because of mutations of IgL genes (Arakawa 
et al., 2004). Because the latter cells overexpressed AID, the 
mutation  frequency  would  be  expected  to  be  somewhat 
higher than in the cells we used that produce limiting amounts 
of AID (Arakawa et al., 2004). In accord with the SHM pattern 
of the IgL gene in DT40 cells, transversions were frequent.
The mutated stop codon by G-to-C transversion, TAC, is 
yet  another  hotspot  for  AID.  Because  there  were  several 
sorted GFP+ cells containing mutations in GFP but not in the 
stop codon, a fraction of the sorted cells apparently reverted 
TAC back to the TAG stop codon while the green cells were 
cultured (Fig. 4 A and Fig. 5). In addition, cells lost the green 
color, presumably because of internal GFP mutations. There 
are AID hotspots in the chromophore itself (Thr-Tyr-Gly) as 
well as in the rest of the GFP protein. The entire 27-kD poly-
peptide structure is essential for the development and mainte-
nance of fluorescence (Olympus FluoView Resource Center 
at http://www.olympusfluoview.com/). Thus, many sites in 
transcription of the transgenes, we measured GFP mRNA 
levels by quantitative real-time PCR. Five C-GFP clones 
and five A-GFP clones were selected that expressed very 
similar levels of GFP mRNA (P > 0.1; Fig. 2).
The transgenes with C-GFP, but not those with A-GFP,  
are mutable in all transfectants
From each transgenic clone, 12 subclones were derived by 
single-cell sorting of GFPIgM+ cells. IgM+ cells were cho-
sen to eliminate potential differences in growth efficiency 
between IgM+ and IgM cell cultures. To determine the ef-
fect of the CAGGTG motif on SHM targeting, C-GFP and 
A-GFP subclones were cultured individually and GFP fluo-
rescence was measured by flow cytometry weekly for 6 wk. 
When assayed in this manner, all C-GFP transgenic clones 
showed GFP+ subclones and, overall, 54 out of 60 subclones 
showed GFP+ cells. On the other hand, only two of the 
AAGGTG clones showed any significant numbers of GFP+ 
cells and, overall, only 18 out of 60 AAGGTG subclones 
showed any GFP+ cells during the 6-wk-long experiment 
(Fig. 3). The differences of observed GFP+ cells between C-
GFP subclones and A-GFP subclones were highly significant 
(P < 0.00001). The mean frequencies of GFP+ cells in 106 
cells were also higher in C-GFP clones, ranging between 20 
and 60, whereas A-GFP clones were consistently <10 GFP+ 
cells/106 cells (Fig. 4 B).
There were many C-GFP subclones with >100 GFP+ 
cells/106 cells at each week (22 C-GFP subclones; Fig. 3, 
green), and some had high numbers of GFP+ cells for 4–5 wk. 
In contrast, A-GFP subclones showed only a few subclones 
with high numbers of GFP+ cells (four A-GFP subclones). 
To verify expression of functional GFP by C-GFP and A-
GFP clones, subclones with a high number of GFP+ cells 
were sorted and cultured for 1 wk. Indeed, FACS analyses 
showed that most of the GFP+ cells in C-GFP clones could 
be cultured (Fig. 4 A), whereas only the GFP+ cells of one 
A-GFP subclone (A2) survived (the others may have been 
autofluorescent dying cells).
Because the levels of transcripts of the C-GFP and A-
GFP transgenes were equivalent in the 10 clones (Fig. 2), this 
Figure 2.  Relative mRNA expression of C-GFP and A-GFP transgenes. Relative mRNA levels among five single-copy clones for eGFP and AID from 
C-GFP and A-GFP lines were measured by real-time PCR. The data show the mean of three independent experiments. -Actin mRNA was used to normal-
ize eGFP and AID mRNA levels. The y axis shows mRNA levels relative to clone C6.408 Targeting of somatic hypermutation | Tanaka et al.
mutability differences of C-GFP and A-GFP transgenes are 
dependent on AID-mediated SHM (Fig. 6).
No correlation between mutation frequency and DNase I 
hypersensitive sites
Between rearranged Ig alleles, which are mutable, and unrear-
ranged Ig alleles, there ware dramatic differences in DNase I 
hypersensitive sites (Storb et al., 1986;  Thompson and Neiman,   
1987). To investigate factors leading to differences in C-GFP 
and A-GFP mutation frequencies, the overall accessibility 
of DNA between C-GFP and A-GFP clones within the 
transgene-specific  region  was  examined  by  treating  nuclei 
with DNase I (Fig. 7). The digestibility of the two C-GFP 
clones appears greater than that of the A-GFP clones (Fig. 7 A).   
However,  the  ethidium  bromide–stained  gel  showed  that   
there was less DNA in the C-GFP clones, and overall, the DNA   
was more digested with lower amounts of DNA (Fig. 7 B). 
Thus, the digestability is equal. This is also supported by re-
probing the Southern blot with an ovalbumin probe: the oval-
bumin gene is also more digested in the C-GFP clones (Fig. 7 C).   
The ovalbumin gene is not expressed in DT40; therefore, 
one does not see DNase I hypersensitive sites but an overall 
GFP must remain unchanged for green color but are susceptible   
to inactivating changes by SHM. We also sequenced the GFP 
transgene of unsorted cells after 6 wk of culture and found a 
few mutations, but none at the stop codon.
The GFP mutations depend on AID
To determine whether C-GFP transgenes were mutated by 
an  AID-dependent  mechanism,  C-GFP  and  A-GFP  con-
structs were transfected into AID/ Cre DT40 or the paren-
tal clone, AID+ Cre DT40, and six independent clones were 
selected for each of the four combinations (Fig. 6). There 
were no significant differences in GFP mRNA levels be-
tween AID/ and AID+ cells (Fig. S1). The AID+ but not 
the AID/ cells expressed AID mRNA (Fig. S1). The flow 
cytometry assay of GFP showed no GFP+ cells in the AID/ 
background in both C-GFP and A-GFP clones. However, in 
the AID+ cells, mutations were significant for C-GFP clones. 
Out of the six A-GFP clones, only two showed sporadic, 
very low numbers of GFP+ cells. We assume that, as in the 
experiments shown in Fig. 3, in the A-GFP clones of Fig. 6, 
the transgene was inserted near CAGGTG sites (see CAG-
GTG motifs near... and Fig. 10). The data indicate that the 
Figure 3.  Percentage of GFP+ cells from C-GFP and A-GFP clones. 60 subclones each from C-GFP and A-GFP lines were monitored for GFP+ cells 
by flow cytometry every week for 6 wk. Green boxes are subclones with numbers of GFP+ cells ≥0.01% or 100 GFP+ cells/106 cells. Bolded borders indicate 
subclones that were sorted for GFP+ cells; red (black) borders indicate sorted subclones that did (did not) expand or survive for subsequent analyses.JEM VOL. 207, February 15, 2010 
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(50×),  but  it  was  diminished  by  an  unlabeled  CAGGTG 
competitor  probe  (unpublished  data).  Because  one  of  the 
known factors binding to CAGGTG are homodimers of E47, 
we included anti-E47 or IgG control antibodies in the bind-
ing reaction. Clearly, inhibition of the protein–DNA com-
plexes  was  observed  with  anti-E47  antibody  for  all  three 
CAGGTG probes (Fig. 8 B). We also used nuclear extracts of 
DT40 cells expressing a human E47 transgene and observed 
inhibition of the protein–DNA complexes with anti–human 
E47 antibody as well (unpublished data). These results sug-
gest  that  the  predominant  protein  binding  specifically  to 
CAGGTG motifs, but not to AAGGTG motifs, is likely to 
be E47. If the binding of E47 to the CAGGTG motif leads 
to targeting of SHM to the E47-bound gene, it may be in-
volved in a direct recruitment of AID and SHM factors. 
However, in our EMSA conditions, we did not observe dif-
ferences in protein–DNA binding patterns between AID+ 
and AID null nuclear extracts (Fig. S2).
Histone acetylation of the GFP transgene
One of the known functions of E47 is the recruitment of the 
SAGA histone acetyltransferase complex (Massari et al., 1999). 
To determine whether there were differences in the histones 
associated with C-GFP and A-GFP, chromatin immunopre-
cipitation  (ChIP)  assays  were  performed  using  antibodies 
against acetylated H3 and H4 histones. ChIP results from 
both histones H3 and H4 showed no significant differences 
between C-GFP and A-GFP clones (Fig. 9; primers for ChIP 
PCR are shown in Fig. 1). This result suggests that the pref-
erential targeting of SHM to the C-GFP transgene is not 
caused by hyperacetylation of histones H3 and H4 when E47 
can interact with the transgene.
Collectively with the DNase I hypersensitivity data, these 
findings suggest that the difference in SHM targeting triggered 
increasing digestion with increasing DNase I. Among C-
GFP clones, there was no variability in hypersensitive sites 
despite the differences in integration sites (Fig. 7 D). This was 
true among A-GFP clones as well. However, contrary to our 
expectation, DNase I hypersensitive sites for C-GFP and A-
GFP clones also showed identical patterns (Fig. 7 D). Thus, 
it appears that the C-GFP and A-GFP transgenes exist in 
equally accessible chromatin.
Protein binding to CAGGTG
To study the possibility that a protein bound to CAGGTG 
may mediate an increase in SHM targeting, each of the three 
CAGGTG and AAGGTG motifs in the transgenes was as-
sayed for protein binding by EMSA. Nuclear extracts of pa-
rental DT40 (CL18) cells showed a specific protein binding 
band with all probes containing the CAGGTG motif that 
was not seen with the AAGGTG motif (Fig. 8 A). This pro-
tein binding specific to the CAGGTG motif was not affected 
by the presence of an unlabeled AAGGTG competitor probe 
Figure 4.  FACS-sorted GFP+ cells from a C-GFP clone and mean 
frequency of GFP+ cells. (A) GFP+ cells were sorted and cultured for 1 wk 
to verify functional GFP expression (percentages are shown). (B) Mean 
numbers of GFP+ cells/106 cells. Each open square indicates a clonal mean 
of 12 subclones for C-GFP; filled triangles show A-GFP. The blue line with 
closed squares and the red line with triangles show means of all C-GFP 
and A-GFP clones, respectively. The entire experiment was performed 
twice with similar results: once without selection of cells with a single-
copy transgene (not depicted) and the second time in a more stringent 
comparison with all clones having only a single-copy transgene, as re-
ported in this paper. FSC, forward scatter.
Figure 5.  Mutation analysis of sorted GFP+ C-GFP clones. Sorted 
GFP+ cells were cultured for 1 wk, and 736 bp of the eGFP gene were 
cloned for sequencing analyses. From a total of 141 sequences, 121 con-
tained a mutation at the G nucleotide (bp 1,099) of the premature stop 
codon. The x and y axes indicate the basepair of the transgene and the 
number of mutations, respectively. These were mostly G-to-C transver-
sions. GFP+ cells were selected after either 2 or 4 wk of culture.410 Targeting of somatic hypermutation | Tanaka et al.
the mutability of the GFP transgene. We found two potential 
PU.1 binding sequences; however, unlike PU.1 motifs found in 
proximity to CAGGTG in Ig enhancers, they were far from the 
CACCTG motifs in the A2 and A9 integration site. This find-
ing and the enhanced mutability seen in transgenic mice with 
CAGGTG in the J region without other nearby motifs found in 
Ig enhancers (Michael et al., 2003) suggest that the presence of 
CAGGTG in a context other than an Ig enhancer may aid the 
targeting of SHM to a nearby gene (see Discussion).
DISCUSSION
The findings reported in this paper show that SHM occurs in 
transgenes containing CAGGTG but not those without CAG-
GTG. The only difference between the C-GFP and A-GFP 
clones is a C-to-A mutation in three CAGGTG motifs in the 
Ig enhancers. The C-GFP and A-GFP transgenic constructs are 
transcribed into identical GFP mRNA sequences and their 
only differences, CAGGTG versus AAGGTG, lie after the 3 poly 
by the presence or absence of the CAGGTG cis-element is 
not caused by changes in accessibility of the target gene; 
rather, it may be caused by a specific recruitment of AID and 
other SHM machinery mediated by E47 protein bound to 
the CAGGTG cis-element.
CAGGTG motifs near the integration site of mutated  
A-GFP clones
Sequencing of sorted GFP+ cells from A2 subclones showed 
mutations at the premature stop codon. Because the hexamer 
motif, CAGGTG, is in theory present once every 4 kb of 
the genome, we sought to determine whether a CAGGTG 
motif is present in the neighborhood of the A-GFP transgene 
integration site in the mutated A2 clone. Cloning of a frag-
ment containing the integration site showed that the A2 clone 
has two CACCTG motifs 1 kb downstream from the 3end 
of the transgene (Fig. 10). The presence of these motifs might 
have induced the targeting of SHM to the A-GFP transgene 
in this particular clone. Because the chicken genome sequence 
is incomplete and a contig for this particular integration site is 
unavailable, we were only able to match this integration site 
with a cDNA library from chicken. Therefore, the chromo-
some and nature of this genomic region is uncertain.
To determine whether unmutated A-GFP clones lack the 
CAGGTG motif nearby, we attempted to sequence integra-
tion sites from these clones. Surprisingly, the A9 clone had an 
identical integration site as the A2 clone. Although we did not 
observe a significant number of GFP+ cells in the A9 sub-
clones, upon random sequencing of GFP in unsorted A9-1 
cells grown for 6 wk, we did observe two transition mutations 
upstream of the GFP gene out of eight sequences (Fig. 10). 
This is consistent with the idea that the CAGGTG cis-element 
can positively influence SHM targeting of a nearby gene.
We have searched for other Ig enhancer motifs near the in-
tegration site of the A2 and A9 clones that may have enhanced 
Figure 7.  DNase I hypersensitive sites of GFP transgenes. (A) South-
ern blot of two C-GFP and two A-GFP subclones. DNA from DNase I– 
digested cells was digested with Pst I and Bcl I and hybridized with a GFP 
probe. 0, 10, and 50 U DNase I are indicated by the filled horizontal ar-
rows. (B) Ethidium bromide–stained gel of DNA fragments before hybrid-
ization for A. (C) An ovalbumin probe was used to reprobe the blot in A. 
(D) Vertical arrows indicate DNase I hypersensitive sites observed with GFP 
for C-GFP and A-GFP clones. The horizontal blue box indicates the probe. 
The experiment was repeated with DNase I digestion of different C-GFP 
and A-GFP cell clones showing no difference in DNase hypersensitivity.
Figure 6.  C-GFP and A-GFP clones in an AID-deficient back-
ground. Six transgenic clones each from Cre DT40 or AID/ Cre DT40 
lines were monitored for GFP+ cells by flow cytometry. The 24 subclones 
were analyzed by FACS weekly for 4 wk. Green boxes are as in Fig. 3.JEM VOL. 207, February 15, 2010 
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SHM still existed in cells with E2A deletion (Schoetz et al., 
2006; Kitao et al., 2008).
The finding that only transgenes with CAGGTG motifs 
attract AID shows that the other cis-elements of Ig enhancers 
alone cannot attract the SHM machinery. However, proteins 
that bind to other motifs in Ig enhancers may be cofactors in 
SHM. The avid targeting of Ig genes compared with non-Ig 
genes may be caused by the combined action of CAGGTG 
binding factors with factors that bind other Ig enhancer mo-
tifs. Mutation of PU.1 or NF-EM5 motifs in the 3  en-
hancer was found to reduce the mutation rate in a  transgene   
(Kodama et al., 2001). The available evidence on enhanced 
mutability by additional CAGGTG motifs in a J region of 
RS-transgenic mice without other adjacent Ig enhancer mo-
tifs (Michael et al., 2003; Fig. S3), as well as finding low mu-
tagenesis  in  A2  and  A9  clones  with  CACCTG  elements 
present within 1 kb of the transgene outside of enhancers 
(Fig. 10), may indicate that the CAGGTG motif and other 
cis-elements need not be at the same site. The CAGGTG 
motif and other potentially required motifs for SHM target-
ing may act independently or coordinately over some dis-
tance. Furthermore, mutations of the Bcl6 gene and other 
non-Ig genes imply that the presence of CAGGTG in or near 
a gene that has the appropriate conditions, such as transcrip-
tion activity and chromatin configuration similar to Ig genes, 
is able to attract the SHM machinery.
A known downstream effect of E2A binding is the recruit-
ment of p300 and SAGA histone acetyltransferase complexes 
(Massari et al., 1999). Acetylated histones H3 and H4 were 
suggested to allow SHM induction in the V region of mutating 
BL2 cells (Woo et al., 2003) or the IgL locus in DT40 cells 
A site. Because the mRNA terminates 5 of the CAGGTG/
AAGGTG sites, it is extremely unlikely that the GFP mRNAs 
from these transgenes have different structures or stability. 
Therefore, finding the same transgene mRNA levels in the 
C-GFP and A-GFP transgenes should reflect equal mRNA 
transcription efficiency. Thus, the effect on mutability seems 
independent of transcription activity, chromatin acetylation, 
or overall target gene activity. It seems unlikely that within the 
C-GFP pools only the cells that mutated were only at that 
time in more accessible chromatin than the rest of the cells; 
there is no precedence where a well-transcribed gene is in a 
heterochromatic state most of the time. The results show that 
the CAGGTG cis-element in the context of Ig enhancers is 
sufficient and likely required to attract AID to a target gene.
There are several studies showing a requirement for Ig en-
hancers for SHM induction (for review see Longerich et al., 
2006). It was also clearly shown that CAGGTG, an element 
of Ig enhancers, enhances SHM (Michael et al., 2003). How-
ever, it was not known whether CAGGTG was sufficient/
required for SHM. CAGGTG is a binding site for E2A pro-
teins. In previous studies, the IgL enhancer of DT40 was 
not required for SHM (Yang et al., 2006); however, an ele-
ment 3 of the enhancer that contains five predicted E2A 
binding sites was required when the enhancer was deleted 
(Kothapalli et al., 2008; Blagodatski et al., 2009). This sup-
ported the idea that E2A proteins may be required for SHM. 
In the present study, the EMSA assays (Fig. 8) show that 
there are clear differences in protein binding to CAGGTG- 
versus AAGGTG-containing probes. Furthermore, the pro-
teins binding to CAGGTG sequences were inhibited by 
addition of anti-E47 antibody, suggesting that the E47 pro-
tein may be the one that leads to increased targeting of SHM 
to the GFP transgene. Besides E47, there may be other 
known or unknown helix-loop-helix proteins that are in-
volved or can substitute in experiments where low levels of 
Figure 8.  EMSA on CAGGTG binding protein. (A) Each CAGGTG and 
AAGGTG motif present in Ei and 3E of the transgenes was assayed for 
protein binding. Nuclear lysates from DT40 CL18 cells were used. (B) EMSA 
in the presence of antibodies. 15 µg of nuclear extract and 1 µg anti-E47 
or IgG control antibodies were used. EMSA assays were repeated at least 
three times.
Figure 9.  ChIP assays of the GFP transgenes. (A and B) ChIP with 
antibodies against acetylated histone H3 (A) and H4 (B). Vertical bars 
indicate mean percentages of immunoprecipitated eGFP DNA over input 
DNA by quantitative PCR. The data represent means and SDs of three 
independent experiments.412 Targeting of somatic hypermutation | Tanaka et al.
determined whether non-Ig genes that show no significant 
mutations in wild-type mice possess a special mechanism 
that prevents error-prone repair. Alternatively, the lack of 
mutations in most non-Ig genes may actually reflect what is 
also going on in Ig genes that have been targeted by AID 
(Storb et al., 2009). In Ig genes of Ung/MMR null mice 
there are about twice as many transitions at C/G than in 
wild-type mice despite about the same mutation frequencies 
overall (Rada et al., 2004; Shen et al., 2006; Storb et al., 
2009). C/G transitions in these null mice are footprints of 
AID. Thus, a conservative calculation shows that in wild-
type mice, 39–47% or more of the uracils created in Ig genes 
by AID are repaired error free (Storb et al., 2009). In the 
study by Liu et al. (2008), the non-Ig genes show mutations 
in Ung/MMR null mice at very low frequencies. If, indeed, 
in Ung/MMR wild-type mice one half or more of AID-
induced mutations in non-Ig genes are also repaired error 
free, they are difficult or impossible to detect because of the 
background of PCR errors. Furthermore, even the groups 
of genes with the least mutations (groups II and III in Liu 
et al. [2008]) in wild-type mice have 35% of their rare mu-
tations at A/T and 20% of transversions at C/G; thus, they 
did undergo error-prone repair in wild-type mice. There-
fore, it seems that uracils in non-Ig genes targeted by AID 
can also be processed by error-prone repair. It will be very 
interesting to learn if and how the same genes can be treated 
either by high-fidelity or error-prone repair, or whether 
there simply are situations where the high-fidelity repair ca-
pacity is overwhelmed by excess uracils in the genome.
The important take-home message from the findings of 
Pasqualucci et al. (2001) and Liu et al. (2008) are that AID 
may attack most non-Ig genes, at least those that are ex-
pressed, and that CAGGTG may be required to target AID 
to any gene, at least under conditions of limited AID levels 
as they exist during SHM. Parsa et al. (2007) and Wang et al. 
(2004) found that transfected non-Ig genes inserted at vari-
ous places in the genome can also be mutated without Ig   
enhancers. These non-Ig transgenes contained multiple CAG-
GTG as well as CAGCTG sites. Thus, these publications 
agree with our finding in this paper that CAGGTG is clearly 
(Kitao et al., 2008). On the other hand, the ChIP data reported 
in this paper from DT40 cells and by others from mouse B cells 
(Odegard et al., 2005) suggested that changes of acetylated his-
tones do not play a major role in inducing SHM. The highly 
transcribed Ig loci in mature B cells as well as developing B cells 
seem to be occupied by acetylated histones (McMurry and 
Krangel, 2000; Nambu et al., 2003; Osipovich et al., 2004). It 
is possible that the highly active transcription from the CMV 
promoter in the present study may have caused equally high 
acetylation of histones H3 and H4 in C-GFP and A-GFP cells; 
nevertheless, mutability was not rescued in A-GFP cells.
The CAGGTG motif is present in all of the frequent 
targets of SHM. Diffuse large B cell lymphomas undergo 
SHM of Ig genes as well as certain non-Ig genes. Searching 
non-Ig genes in diffuse large B cell lymphoma sequences re-
vealed CAGGTG motifs in both mutated and several un-
mutated genes (unpublished data; Pasqualucci et al., 2001). 
However, some of the unmutated genes did not contain any 
CAGGTG motif within the coding regions, whereas all of 
the mutated genes observed contained at least one CAG-
GTG motif. Because this hexamer motif, theoretically, is 
present every 4 kb, it is unlikely that all CAGGTG motifs 
in the genome of activated B cells are associated with DNA 
binding proteins. Therefore, whether CAGGTG motifs are 
associated with E2A proteins may determine whether AID 
associates efficiently with the respective gene.
An extensive analysis of dozens of genes expressed in mu-
tating B cells has shown that essentially all of these genes un-
dergo some level of SHM (Liu et al., 2008). This was revealed 
by checking mutations in mice with deletions of both Ung and 
Msh2. Because most of the genes had no significant mutations 
in wild-type mice, the authors concluded that most non-Ig 
genes in mutating B cells are accessed by AID but protected 
from mutation by restriction of error-prone repair to Ig genes 
and some non-Ig genes, such as BCL6. Other genes would suf-
fer C deamination by AID, but the uracil would be repaired   
error free by base excision repair and mismatch repair (MMR).
An important finding of this report by Liu et al. (2008) 
is that most of the genes that can interact with AID have 
CAGGTG motifs nearby within 2 kb. It remains to be 
Figure 10.  Integration site of mutated A-GFP clones. From A2 and A9 clones (Fig. 3), Stu I–digested DNA fragments containing the transgene and 
adjacent integration sites were isolated and sequenced. Bold lines indicate genomic chicken DNA. Nearby CACCTG motifs in the genomic DNA are indi-
cated. Arrows indicate chicken cDNA sequences and the shaded portions align with the isolated Stu I fragments. Asterisks indicate mutations found in the 
unsorted A9-1 subclone after 6 wk of culture.JEM VOL. 207, February 15, 2010 
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live cells on an LSR II (BD) using CL18 cells and GFP+ pseudo-V KO (a gift 
of H. Arakawa and J.M. Buerstedde; Arakawa et al., 2004) as gating controls.
RT-PCR analysis.  Total RNA was made from DT40 cells with RNA STAT-60   
(Tel-Test Inc.), recovered in 50 µl, and stored at 80°C. Equal amounts of RNA 
were used for making cDNA by the SuperScript III First-Strand Synthesis Sys-
tem for RT-PCR (Invitrogen). Real-time PCRs were run and analyzed on an 
MYiQ system with SYBR Green SuperMix (both from Bio-Rad Laboratories).   
Primers  used  were  eGFP  Fwd4  (5-CCTACCAGGGATCCACCGGTCG-3), 
eGFP Rev3 (5-GATCGCGCTTCTCGTTGGGGTCTTTGCTCA-3),   
ggActin1 (5-CCCCAAGCTTACTCCCACAGCCAGCCATGG-3),  gg-   
Actin2 (5-GGCTCTAGATAGTCCGTCAGGTCACGGCCA-3), ggAID1 
(5-GTTTCTGTGCACCAGAGGGCTGAACA-3),  and  ggAID4  (5- 
CTCCTTTCTTGGCTGGGTGAGAGGTC-3). PCR conditions were   
95°C for 30 s, 64°C for 45 s, and 72°C for 60 s for 40 cycles. The data from 
chicken actin were used as a reference for the relative quantification of eGFP 
or AID cDNA levels using the Pfaffl method (Pfaffl, 2001).
Identification of somatic mutations. Mutations in a transgene were de-
tected by PCR cloning using Pfu polymerase (Agilent Technologies), and 
eGFP  primers  Fwd2  (5-TTTCTGCTGCTGCTTGCGTACGG-3)  and 
Rev6  (5-GCCGTTCTTCTGCTTGTCGGCCATGATATAG-3)  were 
used for PCR cloning with Pfu polymerase at 95°C for 30 s, 58°C for 30 s, 
and 72°C for 90 s for 24 cycles and cloned into a PCR cloning kit (Zero Blunt 
TOPO; Invitrogen). DNA sequencing were performed by the University of 
Chicago Cancer Research Center DNA Sequencing Facility.
Mapping DNase I hypersensitive sites. Nuclei from DT40 cells were 
isolated and digested as previously described (Sambrook, 2001) with modi-
fied lysis buffer containing 0.05% NP-40. 107 DT40 cells were used for each 
digestion with 0, 10, and 50 U DNase I (Applied Biosystems) in 250 µl of 
solution. Isolated DNA was digested with Pst I and Bcl I (New England Bio-
labs, Inc.), and a Sac I/BsrG I fragment from eGFP was used to make a probe 
using a random-priming synthesis kit (Roche) for Southern blot analysis.
ChIP. ChIP assays for acetylated histones H3 and H4 were performed as 
previously described (Agata et al., 2001) with few modifications. For shear-
ing chromatin, 10 U MNase (Sigma-Aldrich) was used in buffer containing 
50 mM Tris, 1 mM CaCl2, and protease inhibitors (Roche) at 37°C. Anti-
bodies used were anti–acetyl histone H3 or anti–acetyl histone H4 (both 
from  Millipore).  Primers  for  the  GFP  region  were  eGFP  Fwd4  (5-
CCTACCAGGGATCCACCGGTCG-3) and eGFP Rev1 (5-TGCCG-
GTGGTGCAGATGAACTTCAGGGTCA-3) to amplify a 185-bp fragment.   
For quantification, the quantitative RT-PCR conditions using SYBR green 
described in RT-PCR analysis were used.
EMSA.  Nuclear  extracts  were  prepared  as  described  by  Dignani  et  al. 
(1983).  The  EMSA  was  performed  as  previously  described  (Bain  et  al., 
1993;  Spaulding  et  al.,  2007).  Oligonucleotides  used  for  EMSA  assays 
were  22mers:  Ei  (5-CCAGGCAGGTGGCCCAGATTAC-3),  A-Ei 
(5-CCAGGAAGGTGGCCCAGATTAC-3),  3E1  (5-CAAAGCCT-
CATACACCTGCTCC-3),  A-3E1  (5-CAAAGCCTCATAAACCT-
GCTCC-3),  3E2  (5-TACCCCAGCACCTGGCCAAGGC-3),  and 
A-3E2 (5-TACCCCAGAACCTGGCCAAGGC-3). These oligonucle-
otides were annealed to the complementary strand and labeled with P32-
ATP using polynucleotide kinase. Approximately 0.1 ng of labeled probe 
was added to 10 µg of nuclear extract in binding buffer containing 1 µg 
BSA/0.8 µg poly-d(I)d(C). Competitor oligonucleotides were added to pro-
tein for 10 min before labeled probe, and the mixture was incubated for a 
further 20 min at room temperature. Antibodies used were anti-E47 and 
control IgG (Santa Cruz Biotechnology, Inc.).
Online supplemental material. Fig. S1 shows relative mRNA expres-
sion for GFP, AID, and -actin. Fig. S2 depicts an EMSA to test whether 
AID associates with the CAGGTG motif. Fig. S3 shows the location of 
an enabler of SHM without leading to increased transcrip-
tion or chromatin activation of the target gene. We postulate 
that AID may be directed to expressed genes that are associ-
ated with CAGGTG elements through the interaction of   
E-box proteins, such as E47, bound to CAGGTG, either 
with AID and the transcription complex or with the tran-
scription complex alone, thus somehow enabling AID access 
to the transcribed gene. Ig genes may be the most highly 
mutated genes because of the coincidence of several condi-
tions: very active transcription, a high proportion of CAG-
GTG sites that are located within the gene, and SHM-favoring 
combinations of other cis-elements present in the enhancers. 
Many mouse and human Ig genes contain CAGGTG motifs 
besides the several present in the enhancers (unpublished 
data).  The  enhanced  mutability  by  additional  CAGGTG 
motifs in a J region of RS transgenic mice (Michael et al., 
2003) indicates that CAGGTG motifs located within genes 
can increase SHM targeting. The distance of CAGGTG to 
the target may also play a role. The A2 and A9 A-GFP clones 
with two distant CACCTG sites 1 kb 3 of the A-GFP 
transgene have a 5.6 times lower mutation frequency than 
the average C-GFP transgene (based on the number of GFP+ 
cells). The relative roles of numbers and distance from the 
target of CAGGTG motifs and their vicinity to enhancers 
are not known. It will be important to determine whether 
CAGGTG alone can suffice to attract AID and, if not, which 
other motifs of Ig enhancers are essential.
As suggested by a transcription model of SHM (Peters 
and Storb, 1996; Michael et al., 2003), E-box proteins bound 
to CAGGTG motifs in Ig enhancers may associate with the 
transcription complex and facilitate binding of AID to the 
RNA polymerase. This and other models implicating CAG-
GTG but not requiring the tethering of AID to the transcrip-
tion complex remain to be investigated.
MATERIALS AND METHODS
Cell culture and transgenic clones. DT40 CL18 cells derived from avian 
leukosis virus–induced chicken bursal B cells were a gift of H. Arakawa and 
J.M. Buerstedde (Institute of Molecular Radiology, Neuherberg, Germany; 
Arakawa et al., 2002). The cells were cultured in RPMI 1640 with 1% 
penicillin/streptomycin, 1% l-glutamine (Invitrogen), 1% chicken serum, 
and -mercaptoethanol (Sigma-Aldrich) at 39.5°C with 5% CO2. C-GFP 
and A-GFP constructs were linearized with Blp I and transfected as previ-
ously described (Arakawa et al., 2004). After 12 h, transfected cells were 
treated with 2 mg/ml G418 for selection of neomycin resistance and single 
clones were isolated by subsequent limiting dilutions. Single clones from 
limiting dilutions were expanded to collect their genomic DNA for PCR 
analysis using a 5 primer from the CMV promoter and a 3 primer from the 
eGFP gene. For analyzing copy numbers of the transgene, Pst I, which cuts 
inside the transgene, as well as Stu I and Spe I, noncutters of the transgene, 
were used to digest genomic DNA. A radioactive probe for eGFP was used 
for Southern blot analysis.
Flow-cytometric analysis and cell sorting. Five C-GFP and five A-GFP 
DT40 clones with a single copy of the transgene were stained with PE-
conjugated anti–chicken IgM antibody (Santa Cruz Biotechnology, Inc.) and 
sorted for sIgM+GFP single cells on a cell sorter (FACSAria; BD) at the Uni-
versity of Chicago Flow Cytometry Facility. 60 C-GFP and 60 A-GFP sub-
clones derived from sorting were monitored for GFP expression of 50,000 414 Targeting of somatic hypermutation | Tanaka et al.
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